Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Reviva Pharmaceuticals Holdings, Inc. (RVPH : NSDQ)
 
 • Company Description   
Reviva Pharmaceuticals Inc. is a clinical stage pharmaceutical company. It engages in developing therapies to address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic and inflammatory diseases. The company's lead product candidate includes RP5063, for the treatment of schizophrenia, bipolar disorder and major depressive disorder. Reviva Pharmaceuticals Inc., formerly known as Tenzing Acquisition Corp., is based in NEW YORK.

Number of Employees: 5

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.65 Daily Weekly Monthly
20 Day Moving Average: 80,032 shares
Shares Outstanding: 13.98 (millions)
Market Capitalization: $51.03 (millions)
Beta: -0.11
52 Week High: $15.10
52 Week Low: $3.29
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -2.14% 0.91%
12 Week -17.98% -18.79%
Year To Date -58.26% -67.06%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
19925 STEVENS CREEK BLVD. SUITE 100
-
CUPERTINO,CA 95014
USA
ph: 408-501-8881
fax: -
None http://www.revivapharma.com
 
 • General Corporate Information   
Officers
Laxminarayan Bhat - ChiefExecutiveOfficerandDirector
Parag Saxena - Chairman of the Board
Narayan Prabhu - ChiefFinancialOfficer
Richard Margolin - Director
Purav Patel - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 76152G100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 03/28/22
Share - Related Items
Shares Outstanding: 13.98
Most Recent Split Date: (:1)
Beta: -0.11
Market Capitalization: $51.03 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.26 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.65 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/28/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.58
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 36.84%
vs. Previous Quarter: 0.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/21 - -39.59
06/30/21 - -52.46
03/31/21 - -175.68
ROA
09/30/21 - -35.41
06/30/21 - -44.93
03/31/21 - -113.72
Current Ratio
09/30/21 - 34.80
06/30/21 - 31.41
03/31/21 - 6.05
Quick Ratio
09/30/21 - 34.80
06/30/21 - 31.41
03/31/21 - 6.05
Operating Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Net Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Pre-Tax Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Book Value
09/30/21 - 2.31
06/30/21 - 2.58
03/31/21 - 0.49
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - 0.00
Debt-to-Capital
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - 0.00
 

Powered by Zacks Investment Research ©